CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• RUVBL1 and RUVBL2 are ATPases associated with diverse cellular activities (AAAs) crucial for chromatin remodeling and gene expression.
• Overexpression of RUVBL1/2 is linked to oncogenesis, tumor growth, and poor prognosis in various cancers.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting the RUVBL1/2 complex in cancer treatment.
• To evaluate the efficacy and specificity of the small-molecule inhibitor CB-6644.

Main Methods:

• Utilized CB-6644, an allosteric inhibitor targeting RUVBL1/2 ATPase activity.
• Assessed drug-induced cell death and characterized resistance mechanisms via mutations in RUVBL1 or RUVBL2.
• Tested CB-6644 efficacy in xenograft models of acute myeloid leukemia and multiple myeloma.

Main Results:

• CB-6644 specifically interacts with RUVBL1/2 in cancer cells, leading to cell death.
• Acquired resistance mutations in RUVBL1 or RUVBL2 confirm on-target activity.
• CB-6644 significantly reduced tumor growth in leukemia and myeloma xenograft models with no apparent toxicity.

Conclusions:

• Targeting RUVBL1/2 with CB-6644 demonstrates significant therapeutic potential for cancer treatment.
• CB-6644 is a valuable chemical tool for further research into RUVBL biology and cancer therapeutics.